Drug Search Results
More Filters [+]

PD-217,014

Alternative Names: pd-217,014, pd217,014, pd 217,014
Latest Update: 2024-05-16
Latest Update Note: PubMed Publication

Product Description

the treatment of abdominal pain/discomfort associated with irritable bowel disease

Mechanisms of Action: GABA Analogue

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PD-217,014

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Irritable Bowel Syndrome|Neuralgia, Postherpetic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

A4451007

P2

Completed

Irritable Bowel Syndrome

2005-02-01

A4451006

P2

Terminated

Neuralgia, Postherpetic

None

Recent News Events